Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulm...
Gespeichert in:
| Veröffentlicht in: | Lung 2012-06, Vol.190 (3), p.251-262 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 262 |
|---|---|
| container_issue | 3 |
| container_start_page | 251 |
| container_title | Lung |
| container_volume | 190 |
| creator | Willis, Lauren Hayes, Don Mansour, Heidi M. |
| description | Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth. |
| doi_str_mv | 10.1007/s00408-011-9360-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1010077190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A331348831</galeid><sourcerecordid>A331348831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-58aa5d4165dee9de3841c8ec2a3667d5666774f5792ca38d3ab1657499ff6d603</originalsourceid><addsrcrecordid>eNp1kV9rHCEUxaW0NNttP0BfilDom6mOOjqPS9I_gYX0YfssRu_MGmbGrc6k2W9fl03LBrYIV_D-zpV7DkLvGb1klKrPmVJBNaGMkYbXlDy-QAsmeEWYkvQlWlAuGKkKc4He5HxPKVM1k6_RRVVVSiipF-h2s4VkdzBPweF12MUcB9vj67THP-JvDwnfjFvb2ynEEa8glX6fcRsT3tjUwQQer-exw9fQhwdI-7foVWv7DO-e7iX6-fXL5uo7Wd9-u7larYmTVE9EamulF6yWHqDxwLVgToOrLK9r5WVdqhKtVE3lLNee27vCKtE0bVv7mvIl-nicu0vx1wx5MvdxTmP50jB6MEex5oTqbA8mjG2cknVDyM6sOGdcaF3qEpEzVAdjcaaPI7ShPD_jL8_w5XgYgjsr-HQi2ILtp23xcT6Ymp-D7Ai6YnRO0JpdCoNN-7KUOWxljpGbErk5RG4ei-bDkxPz3QD-n-JvxgWojkAurbGDdGrV_6b-ATtEs0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1010077190</pqid></control><display><type>article</type><title>Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Willis, Lauren ; Hayes, Don ; Mansour, Heidi M.</creator><creatorcontrib>Willis, Lauren ; Hayes, Don ; Mansour, Heidi M.</creatorcontrib><description>Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.</description><identifier>ISSN: 0341-2040</identifier><identifier>EISSN: 1432-1750</identifier><identifier>DOI: 10.1007/s00408-011-9360-x</identifier><identifier>PMID: 22274758</identifier><identifier>CODEN: LUNGD9</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Administration, Inhalation ; Aerosols ; Asthma ; Cystic fibrosis ; Drug delivery systems ; Drugs ; Health aspects ; Humans ; Lipids ; Liposomes ; Lung - metabolism ; Lung cancer ; Lung diseases ; Lung Diseases - drug therapy ; Medicine ; Medicine & Public Health ; Nanocapsules ; Nanoparticles ; Pharmaceutical Preparations - administration & dosage ; Pneumology/Respiratory System ; Powders ; Respiratory agents ; Respiratory therapy ; Surface active agents ; Vehicles</subject><ispartof>Lung, 2012-06, Vol.190 (3), p.251-262</ispartof><rights>Springer Science+Business Media, LLC 2012</rights><rights>COPYRIGHT 2012 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-58aa5d4165dee9de3841c8ec2a3667d5666774f5792ca38d3ab1657499ff6d603</citedby><cites>FETCH-LOGICAL-c508t-58aa5d4165dee9de3841c8ec2a3667d5666774f5792ca38d3ab1657499ff6d603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00408-011-9360-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00408-011-9360-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22274758$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Willis, Lauren</creatorcontrib><creatorcontrib>Hayes, Don</creatorcontrib><creatorcontrib>Mansour, Heidi M.</creatorcontrib><title>Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery</title><title>Lung</title><addtitle>Lung</addtitle><addtitle>Lung</addtitle><description>Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.</description><subject>Administration, Inhalation</subject><subject>Aerosols</subject><subject>Asthma</subject><subject>Cystic fibrosis</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Lipids</subject><subject>Liposomes</subject><subject>Lung - metabolism</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Diseases - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nanocapsules</subject><subject>Nanoparticles</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pneumology/Respiratory System</subject><subject>Powders</subject><subject>Respiratory agents</subject><subject>Respiratory therapy</subject><subject>Surface active agents</subject><subject>Vehicles</subject><issn>0341-2040</issn><issn>1432-1750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kV9rHCEUxaW0NNttP0BfilDom6mOOjqPS9I_gYX0YfssRu_MGmbGrc6k2W9fl03LBrYIV_D-zpV7DkLvGb1klKrPmVJBNaGMkYbXlDy-QAsmeEWYkvQlWlAuGKkKc4He5HxPKVM1k6_RRVVVSiipF-h2s4VkdzBPweF12MUcB9vj67THP-JvDwnfjFvb2ynEEa8glX6fcRsT3tjUwQQer-exw9fQhwdI-7foVWv7DO-e7iX6-fXL5uo7Wd9-u7larYmTVE9EamulF6yWHqDxwLVgToOrLK9r5WVdqhKtVE3lLNee27vCKtE0bVv7mvIl-nicu0vx1wx5MvdxTmP50jB6MEex5oTqbA8mjG2cknVDyM6sOGdcaF3qEpEzVAdjcaaPI7ShPD_jL8_w5XgYgjsr-HQi2ILtp23xcT6Ymp-D7Ai6YnRO0JpdCoNN-7KUOWxljpGbErk5RG4ei-bDkxPz3QD-n-JvxgWojkAurbGDdGrV_6b-ATtEs0A</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Willis, Lauren</creator><creator>Hayes, Don</creator><creator>Mansour, Heidi M.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20120601</creationdate><title>Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery</title><author>Willis, Lauren ; Hayes, Don ; Mansour, Heidi M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-58aa5d4165dee9de3841c8ec2a3667d5666774f5792ca38d3ab1657499ff6d603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Administration, Inhalation</topic><topic>Aerosols</topic><topic>Asthma</topic><topic>Cystic fibrosis</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Lipids</topic><topic>Liposomes</topic><topic>Lung - metabolism</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Diseases - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nanocapsules</topic><topic>Nanoparticles</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pneumology/Respiratory System</topic><topic>Powders</topic><topic>Respiratory agents</topic><topic>Respiratory therapy</topic><topic>Surface active agents</topic><topic>Vehicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Willis, Lauren</creatorcontrib><creatorcontrib>Hayes, Don</creatorcontrib><creatorcontrib>Mansour, Heidi M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Lung</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Willis, Lauren</au><au>Hayes, Don</au><au>Mansour, Heidi M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery</atitle><jtitle>Lung</jtitle><stitle>Lung</stitle><addtitle>Lung</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>190</volume><issue>3</issue><spage>251</spage><epage>262</epage><pages>251-262</pages><issn>0341-2040</issn><eissn>1432-1750</eissn><coden>LUNGD9</coden><abstract>Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>22274758</pmid><doi>10.1007/s00408-011-9360-x</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0341-2040 |
| ispartof | Lung, 2012-06, Vol.190 (3), p.251-262 |
| issn | 0341-2040 1432-1750 |
| language | eng |
| recordid | cdi_proquest_journals_1010077190 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Inhalation Aerosols Asthma Cystic fibrosis Drug delivery systems Drugs Health aspects Humans Lipids Liposomes Lung - metabolism Lung cancer Lung diseases Lung Diseases - drug therapy Medicine Medicine & Public Health Nanocapsules Nanoparticles Pharmaceutical Preparations - administration & dosage Pneumology/Respiratory System Powders Respiratory agents Respiratory therapy Surface active agents Vehicles |
| title | Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A57%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20Liposomal%20Dry%20Powder%20Inhalation%20Aerosols%20for%20Targeted%20Lung%20Delivery&rft.jtitle=Lung&rft.au=Willis,%20Lauren&rft.date=2012-06-01&rft.volume=190&rft.issue=3&rft.spage=251&rft.epage=262&rft.pages=251-262&rft.issn=0341-2040&rft.eissn=1432-1750&rft.coden=LUNGD9&rft_id=info:doi/10.1007/s00408-011-9360-x&rft_dat=%3Cgale_proqu%3EA331348831%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1010077190&rft_id=info:pmid/22274758&rft_galeid=A331348831&rfr_iscdi=true |